FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05395052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05395052
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Fate Therapeutics
- Industry
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Interventions
- Amivantamab Combination Product
- Atezolizumab Combination Product
- Avelumab Combination Product
- Cetuximab Combination Product
- Cyclophosphamide Drug
- FT536 Drug
- Fludarabine Drug
- IL-2 Drug
- Nivolumab Combination Product
- Pembrolizumab Combination Product
- Trastuzumab Combination Product
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2022
- Primary completion
- Aug 10, 2023
- Completion
- Aug 10, 2023
- Last update posted
- Sep 20, 2023
2022 – 2023
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | — |
| UCLA Division of Hematology-Oncology | Los Angeles | California | 90404 | — |
| Hackensack University Medical Center - John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05395052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05395052 live on ClinicalTrials.gov.